These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 37547931)

  • 1. Thromboprophylaxis in Hospitalized Non-Critically Ill Patients With Mild-to-Moderate COVID-19 Infection: A Systematic Review and Meta-Analysis.
    Hafiz A; Alkofide H; Al Sulaiman K; Joharji H; Aljohani S; Sarkhi KA; Alharbi R; Korayem GB; AlFaifi M; Alsohimi S; Aljuhani O
    Clin Appl Thromb Hemost; 2023; 29():10760296231191123. PubMed ID: 37547931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose versus low-dose venous thromboprophylaxis in hospitalized patients with COVID-19: a systematic review and meta-analysis.
    Valeriani E; Porfidia A; Ageno W; Spoto S; Pola R; Di Nisio M
    Intern Emerg Med; 2022 Sep; 17(6):1817-1825. PubMed ID: 35759185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials.
    Ena J; Valls V
    Clin Exp Med; 2023 Aug; 23(4):1189-1196. PubMed ID: 36048371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.
    Kahn SR; Morrison DR; Diendéré G; Piché A; Filion KB; Klil-Drori AJ; Douketis JD; Emed J; Roussin A; Tagalakis V; Morris M; Geerts W
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD008201. PubMed ID: 29687454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis.
    Patell R; Chiasakul T; Bauer E; Zwicker JI
    Thromb Haemost; 2021 Jan; 121(1):76-85. PubMed ID: 33378787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation for perioperative thromboprophylaxis in people with cancer.
    Matar CF; Kahale LA; Hakoum MB; Tsolakian IG; Etxeandia-Ikobaltzeta I; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009447. PubMed ID: 29993117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appropriate thromboprophylaxis strategy for COVID-19 patients on dosage, antiplatelet therapy, outpatient, and postdischarge prophylaxis: a meta-analysis of randomized controlled trials.
    Meng J; Tang H; Xiao Y; Liu W; Wu Y; Xiong Y; Gao S
    Int J Surg; 2024 Jun; 110(6):3910-3922. PubMed ID: 38549227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials.
    Bonfim LCMG; Guerini IS; Zambon MG; Pires GB; Silva ACF; Gobatto ALN; Lopes MA; Brosnahan SB
    J Crit Care; 2023 Oct; 77():154344. PubMed ID: 37244209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis.
    Eck RJ; Elling T; Sutton AJ; Wetterslev J; Gluud C; van der Horst ICC; Gans ROB; Meijer K; Keus F
    BMJ; 2022 Jul; 378():e070022. PubMed ID: 35788047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
    Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of two heparin regimens for prevention of venous thromboembolism in hospitalized patients with COVID-19: a meta-analysis.
    Vedovati MC; Graziani M; Agnelli G; Becattini C
    Intern Emerg Med; 2023 Apr; 18(3):863-877. PubMed ID: 36580269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
    Ortega-Paz L; Galli M; Capodanno D; Franchi F; Rollini F; Bikdeli B; Mehran R; Montalescot G; Gibson CM; Lopes RD; Andreotti F; Angiolillo DJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):677-686. PubMed ID: 34519777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Otten HM; Rutjes AW
    Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight heparin for prevention of central venous catheter-related thrombosis in children.
    Pelland-Marcotte MC; Amiri N; Avila ML; Brandão LR
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD005982. PubMed ID: 32557627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials.
    Pilia E; Belletti A; Fresilli S; Finco G; Landoni G
    J Thromb Thrombolysis; 2022 Oct; 54(3):420-430. PubMed ID: 35922578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials.
    Marcucci M; Etxeandia-Ikobaltzeta I; Yang S; Germini F; Gupta S; Agarwal A; Ventresca M; Tang S; Morgano GP; Wang M; Ahmed MM; Neumann I; Izcovich A; Criniti J; Popoff F; Devereaux PJ; Dahm P; Anderson D; Lavikainen LI; Tikkinen KAO; Guyatt GH; Schünemann HJ; Violette PD
    BMJ; 2022 Mar; 376():e066785. PubMed ID: 35264372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
    Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
    JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Longitudinal Study of Thrombosis and Bleeding Outcomes With Thromboprophylaxis in Pregnant Women at Intermediate and High Risk of VTE.
    Schapkaitz E; Libhaber E; Gerber A; Rhemtula H; Zamparini J; Jacobson BF; Büller HR
    Clin Appl Thromb Hemost; 2023; 29():10760296231160748. PubMed ID: 36972476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism.
    Kahn SR; Morrison DR; Cohen JM; Emed J; Tagalakis V; Roussin A; Geerts W
    Cochrane Database Syst Rev; 2013 Jul; (7):CD008201. PubMed ID: 23861035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.